79 related articles for article (PubMed ID: 21300504)
21. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET and CT characterization of adrenal lesions in cancer patients.
Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
[TBL] [Abstract][Full Text] [Related]
23. Correlation of PET/CT standardized uptake value measurements between dedicated workstations and a PACS-integrated workstation system.
Meirelles GS; Kijewski P; Akhurst T
J Digit Imaging; 2007 Sep; 20(3):307-13. PubMed ID: 16972011
[TBL] [Abstract][Full Text] [Related]
24. Correcting tumour SUV for enhanced bone marrow uptake: retrospective 18F-FDG PET/CT studies.
Teo BK; Badiee S; Hadi M; Lam T; Johnson L; Seo Y; Bacharach SL; Hasegawa BH; Franc BL
Nucl Med Commun; 2008 Apr; 29(4):359-66. PubMed ID: 18317301
[TBL] [Abstract][Full Text] [Related]
25. Invited editorial: Response to therapy assessment of colorectal liver metastasis.
Maffione AM; Rampin L; Blickman JG; Rubello D
Eur J Radiol; 2013 Jun; 82(6):903-4. PubMed ID: 23518147
[No Abstract] [Full Text] [Related]
26. The effect of 18F-FDG-PET/CT respiratory gating on detected metabolic activity in lung lesions.
Lupi A; Zaroccolo M; Salgarello M; Malfatti V; Zanco P
Ann Nucl Med; 2009 Feb; 23(2):191-6. PubMed ID: 19225943
[TBL] [Abstract][Full Text] [Related]
27. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
Ho CL; Yu SC; Yeung DW
J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
[TBL] [Abstract][Full Text] [Related]
28. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source.
Papathanassiou D; Becker S; Amir R; Menéroux B; Liehn JC
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1422-8. PubMed ID: 16133387
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT.
Goudarzi B; Jacene HA; Wahl RL
J Nucl Med; 2008 Oct; 49(10):1585-92. PubMed ID: 18794276
[TBL] [Abstract][Full Text] [Related]
30. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values.
Jaskowiak CJ; Bianco JA; Perlman SB; Fine JP
J Nucl Med; 2005 Mar; 46(3):424-8. PubMed ID: 15750154
[TBL] [Abstract][Full Text] [Related]
31. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET.
Kumar R; Loving VA; Chauhan A; Zhuang H; Mitchell S; Alavi A
J Nucl Med; 2005 Nov; 46(11):1819-24. PubMed ID: 16269595
[TBL] [Abstract][Full Text] [Related]
32. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland.
Jadvar H; Ye W; Groshen S; Conti PS
Ann Nucl Med; 2008 Nov; 22(9):787-93. PubMed ID: 19039557
[TBL] [Abstract][Full Text] [Related]
33. PET/CT mediastinal and liver FDG uptake: effects of biological and procedural factors.
Malladi A; Viner M; Jackson T; Mercier G; Subramaniam RM
J Med Imaging Radiat Oncol; 2013 Apr; 57(2):169-75. PubMed ID: 23551774
[TBL] [Abstract][Full Text] [Related]
34. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake.
Davison JM; Ozonoff A; Imsande HM; Grillone GA; Subramaniam RM
Radiology; 2010 May; 255(2):578-85. PubMed ID: 20413767
[TBL] [Abstract][Full Text] [Related]
35. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.
Beaulieu S; Kinahan P; Tseng J; Dunnwald LK; Schubert EK; Pham P; Lewellen B; Mankoff DA
J Nucl Med; 2003 Jul; 44(7):1044-50. PubMed ID: 12843218
[TBL] [Abstract][Full Text] [Related]
36. FDG PET/CT features of ovarian metastasis.
Kitajima K; Suzuki K; Senda M; Kita M; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
Clin Radiol; 2011 Mar; 66(3):264-8. PubMed ID: 21295206
[TBL] [Abstract][Full Text] [Related]
37. Can PET-CT with FDG replace contrast enhanced CT for imaging of liver metastases?
Strauss LG; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1902-5. PubMed ID: 17938920
[No Abstract] [Full Text] [Related]
38. Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology.
Zheng J; Allen C; Serra S; Vines D; Charron M; Jaffray DA
Contrast Media Mol Imaging; 2010; 5(3):147-54. PubMed ID: 20586032
[TBL] [Abstract][Full Text] [Related]
39. Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma?
Vera P; Ouvrier MJ; Hapdey S; Thillays M; Pesquet AS; Diologent B; Callonec F; Hitzel A; Edet-Sanson A; Ménard JF; Jardin F; Tilly H
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1943-52. PubMed ID: 17694309
[TBL] [Abstract][Full Text] [Related]
40. Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in (18)F-FDG PET/CT.
ter Voert EE; van Laarhoven HW; Kok PJ; Oyen WJ; Visser EP; de Geus-Oei LF
Nucl Med Commun; 2014 May; 35(5):472-7. PubMed ID: 24509519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
